GlassScriptPhysician profile
David R Downey
NPI 1225140536
$4,180.92
in general payments reported to CMS, 2019-2025
25 companies · $959 in 2025
The $959 reported for 2025 was more than what 80% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $636 · 2022: $656 · 2023: $1,125 · 2024: $804 · 2025: $959.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,889.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,888.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $746.53 | 2021-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $688.85 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $346.23 | 2021-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $293.66 | 2021-2025 | Verquvo, Capvaxive |
| Astrazeneca Pharmaceuticals LP | $281.43 | 2021-2025 | Farxiga, Brilinta, Lokelma |
| E.R. Squibb & Sons, L.L.C. | $235.07 | 2022-2025 | Eliquis, Camzyos |
| Janssen Pharmaceuticals, INC | $223.38 | 2021-2024 | Xarelto |
| Pfizer INC. | $181.95 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $141.56 | 2022-2023 | |
| Boston Scientific Corporation | $115.47 | 2021-2025 | Watchman |
| Kiniksa Pharmaceuticals International, Plc | $111.34 | 2024 | Arcalyst |
| Actelion Pharmaceuticals US, INC. | $111.06 | 2025 | Uptravi, Opsumit |
| Abbott Laboratories | $103.02 | 2021-2024 | Amplatzer Amulet |
| Edwards Lifesciences Corporation | $101.36 | 2025 | |
| Irhythm Technologies, INC. | $79.72 | 2023-2024 | Zio Xt Patch, Zio Monitor |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $58.43 | 2021-2022 | |
| Medtronic, INC. | $53.07 | 2021-2023 | Micra |
| Scpharmaceuticals INC. | $50.75 | 2024-2025 | |
| Lexicon Pharmaceuticals, INC. | $49.23 | 2023 | Inpefa |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $45.00 | 2023-2025 | Lifevest |
| Bridgebio Pharma, INC. | $44.21 | 2025 | Attruby |
| Bayer Healthcare Pharmaceuticals INC. | $42.95 | 2025 | |
| Novo Nordisk INC | $34.71 | 2025 | Wegovy |
| Kiniksa Pharmaceuticals, LTD. | $21.17 | 2023 | Arcalyst |
| Inspire Medical Systems, INC. | $20.77 | 2025 | Inspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Downey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.